SPONSOR

AstraZeneca

Total Trials

Recruiting

Phases

Phase 1, Phase 2, Phase 4, Phase 3, Phase 1, Phase 2

Conditions studied: Rheumatoid Arthritis Systemic Lupus Erythematosus Paroxysmal Nocturnal Hemoglobinuria Sepsis Acute Kidney Injury Healthy Participants Dyslipidemia Life Threatening Bleeding Factor Xa Inhibitor Severe Asthma

AstraZeneca is a British-Swedish multinational biopharmaceutical company with one of the industry's most active clinical pipelines in oncology, cardiovascular-renal-metabolic disease, respiratory and immunology, and rare diseases. Founded in 1999 through the merger of Astra AB and Zeneca Group, AstraZeneca today invests approximately $9–10 billion annually in R&D. Their trial portfolio is notable for several landmark programs including the DAPA-HF and DAPA-CKD trials (dapagliflozin), the ADAURA and LAURA trials (osimertinib for lung cancer), and the AstraZeneca-Oxford COVID-19 vaccine development.

AstraZeneca's oncology unit — operating as AstraZeneca Oncology — maintains deep expertise in targeted therapy for EGFR-mutated non-small cell lung cancer, HER2-targeted therapies (trastuzumab deruxtecan, developed with Daiichi Sankyo), PARP inhibitors for ovarian and breast cancer (olaparib), and immuno-oncology through the PD-L1 inhibitor durvalumab. The cardiovascular and metabolic portfolio includes one of the most extensive SGLT2 inhibitor trial programs ever conducted, spanning heart failure, chronic kidney disease, and type 2 diabetes across thousands of participants in dozens of countries.

AstraZeneca's clinical trials are conducted at leading academic and community research centers worldwide. The company has made public commitments to diversity in clinical research and has implemented specific protocols to increase enrollment from historically underrepresented groups. AstraZeneca participates in pre-competitive partnerships through organizations such as the Innovative Medicines Initiative (IMI) and TransCelerate BioPharma.

Frequently Asked Questions — AstraZeneca

What is AstraZeneca best known for in clinical research?

AstraZeneca is best known clinically for three major areas: (1) lung cancer — their EGFR inhibitor osimertinib (Tagrisso) demonstrated unprecedented survival improvements in adjuvant NSCLC and is the subject of ongoing trials in earlier disease stages and combination settings; (2) heart failure and kidney disease — dapagliflozin (Farxiga) has been shown in Phase 3 trials to significantly reduce hospitalization and mortality across both heart failure subtypes and in CKD independent of diabetes; and (3) PD-L1 inhibition — durvalumab (Imfinzi) has received approvals in multiple cancer indications and is under investigation in dozens of additional combinations.

Does AstraZeneca run trials outside of cancer?

Yes. While oncology represents the largest share of AstraZeneca's current trial portfolio, the company has equally robust programs in cardiovascular, renal, and metabolic disease (CVRM), respiratory and immunology, and rare diseases. Their CVRM trials include investigations of SGLT2 inhibitors, GLP-1/GIP agonists (in collaboration with partners), and novel mechanisms in heart failure. The respiratory portfolio covers severe asthma (benralizumab, tezepelumab), COPD, and interstitial lung disease. Rare disease trials focus on conditions with high unmet medical need including complement-mediated diseases and severe respiratory disorders.

How does AstraZeneca approach diversity and inclusion in clinical trials?

AstraZeneca has a published global diversity and inclusion framework for clinical trials that sets targets for enrollment of women, patients from racial and ethnic minority groups, and older adults across all Phase 2 and Phase 3 studies. The company works with community organizations and patient advocacy groups to identify and address barriers to participation — including transportation, language, and lack of awareness — particularly for oncology and rare disease trials where underrepresentation has historically been greatest. These commitments are reported annually in AstraZeneca's Global Sustainability Report.

AstraZeneca

Frequently Asked Questions — AstraZeneca

Clinical Trials by AstraZeneca

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Danicopan PMS in Korea

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil

A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia

A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy

A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the Monitoring of Greek pATiEnts With CRSwNP"

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma